Sean Pintchovski, PhD, has 15 years of experience in the pharmaceutical industry. During this time, he successfully led pre-clinical research teams to discover, validate, and advance several small molecules into the clinic, including PTC857 (GBA-Parkinson’s disease and Amyotrophic Lateral Sclerosis) and PTC743 (Friedreich’s ataxia). Additionally, Pintchovski contributed within cross-functional clinical teams to identify novel biomarkers and next-generation technologies needed to advance the use of precision medicine in neurology. He received a BS with Honors from the California Institute of Technology and earned his PhD in Neuroscience from the University of California, San Francisco.